Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose study of ABBV-547 in healthy adults
jRCT2071250150Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Countries
- 2
01
Overview
Phase 1, randomised trial comparing ABBV-547 single dose with Placebo single dose (2 arms). Primary endpoint: Number of Participants with Adverse Events (AEs). Started Apr 2026; status: active, not recruiting.
02
Drugs
ABBV-547
Beyond the preview
Go deeper on jRCT2071250150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250150.